<DOC>
	<DOCNO>NCT02179008</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy five concentration DE-117 ophthalmic solution .</brief_summary>
	<brief_title>Multi-center Phase II Study Assessing Safety Efficacy DE-117 Ophthalmic Solution Subjects With Primary Open-angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This 90-day randomized , observer-masked , active-controlled , parallel-group , multi-center , study assess safety efficacy five concentration DE-117 ophthalmic solution compare latanoprost ( 0.005 % latanoprost ) subject primary open-angle glaucoma ocular hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Current diagnosis primary openangle glaucoma ocular hypertension eye Qualifying intraocular pressure least one eye Baseline Qualifying correct ETDRS visual acuity eye Qualifying central cornea thickness eye Closed/barely open anterior chamber angle history acute angle closure either eye Diagnosis primary openangle glaucoma ocular hypertension due etiology know nonresponsive conventional drug therapy Evidence advance glaucoma , visual field defect progressive visual field loss meet study criterion History ocular surgery specifically intend low IOP History ocular systemic abnormality condition may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Intended current use ocular medication study medication study Use contact lens within one week prior Baseline ( Day 1 ) end treatment Known allergy sensitivity component study medication Use steroid ( systemic ) within 30 day prior Visit 1 ( Screening ) Anticipate need initiate modify exist chronic therapy could substantially affect IOP study outcome study period Females pregnant , nurse planning pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Santen</keyword>
	<keyword>Eye</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>